Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.72 USD | +0.51% | +7.92% | -22.20% |
15/04 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
25/03 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.20% | 2.28B | |
+22.81% | 47.9B | |
+46.56% | 41.42B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-21.00% | 19.27B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
-0.48% | 11.99B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Chardan Research Cuts Price Target on Intellia Therapeutics to $146 From $172, Citing Q2 Results, WT1 Program Update; Buy Rating Kept